• 1
    Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 66394.
  • 2
    Moher D, Schulz KF, Altman DG, et al. Revised recommendations for improving the quality of reports of parallel group randomized trials. 2001. Available at: (accessed 19 July 2007).
  • 3
    Vakil N, Van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 190020; quiz 1943.
    Direct Link:
  • 4
    Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101: 195663.
    Direct Link:
  • 5
    Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397402.
  • 6
    Vakil N. New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 19: 10419.
  • 7
    Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ 1999; 318: 5027.
  • 8
    Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken ‘on-demand’. Aliment Pharmacol Ther 2007; 26: 195204.
  • 9
    Roland M, Torgerson D. Understanding controlled trials: what outcomes should be measured? BMJ 1998; 317: 1075.
  • 10
    Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967; 20: 63748.
  • 11
    Howden CW, Henning JM, Huang B, Lukasik N, Freston JW. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 2001; 96: 170410.
    Direct Link:
  • 12
    Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121: 1095100.
  • 13
    Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100: 232437.
    Direct Link:
  • 14
    Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2004; 2: 6658.
  • 15
    Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006; 131: 390401; quiz 659–60.
  • 16
    Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 34754.
  • 17
    Metz DC, Inadomi JM, Howden CW, Van Zanten SJ, Bytzer P. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol 2007; 102: 64253.
    Direct Link:
  • 18
    Verdu EF, Armstrong D, Idstrom JP, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995; 37: 7438.
  • 19
    Nastaskin I, Mehdikhani E, Conklin J, Park S, Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci 2006; 51: 211320.
  • 20
    Wright CE, Ebrecht M, Mitchell R, Anggiansah A, Weinman J. The effect of psychological stress on symptom severity and perception in patients with gastro-oesophageal reflux. J Psychosom Res 2005; 59: 41524.
  • 21
    Husser D, Bollmann A, Kuhne C, Molling J, Klein HU. Evaluation of noncardiac chest pain: diagnostic approach, coping strategies and quality of life. Eur J Pain 2006; 10: 515.
  • 22
    Biertho L, Sanjeev D, Sebajang H, Antony M, Anvari M. The influence of psychological factors on the outcomes of laparoscopic Nissen fundoplication. Ann Surg Innov Res 2007; 1: 2.
  • 23
    Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134: 65762.
  • 24
    Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295: 115260.
  • 25
    Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 90312.
  • 26
    Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 47382.
  • 27
    Hunfeld NGM, Geus WP, Kuipers EJ. Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther 2007; 25: 3946.
  • 28
    Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med 2007; 32: 4037.
  • 29
    Kim SL, Hunter JG, Wo JM, Davis LP, Waring JP. NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus? J Clin Gastroenterol 1999; 29: 324.
  • 30
    Lundell LR, Miettinen P, Myrvold HE, et al. Anti-reflux surgery compared with maintenance omeprazole for reflux esophagitis. Results after 12 years. Gastroenterology 2007; 4(Suppl. 2): A107.
  • 31
    Greenhalgh T. Assessing the methodological quality of published papers. BMJ 1997; 315: 3058.
  • 32
    Johnson DA, Fennerty MB. Heartburn Severity Underestimates Erosive Esophagitis Severity in Elderly Patients with Gastroesophageal Reflux Disease. Gastroenterology 2004; 126: 6604.
  • 33
    Bayer A, Tadd W. Unjustified exclusion of elderly people from studies submitted to research ethics committee for approval: descriptive study. BMJ 2000; 321: 9923.
  • 34
    European Medicines Agency. Note for Guidance on Studies in Support of Special Populations: Geriatrics (CPMP/ICH/379/95). 1994. Available at: (accessed 6 July 2007).
  • 35
    Sibbald B, Roberts C. Understanding controlled trials. Crossover trials. BMJ 1998; 316: 1719.
  • 36
    Lord SJ, Gebski VJ, Keech AC. Multiple analyses in clinical trials: sound science or data dredging? Med J Aust 2004; 181: 4524.
  • 37
    Food and Drug Administration. Guidance for Industry: E9 Statistical Principles for Clinical Trials. 1998. Available at: (accessed 10 September 2007).
  • 38
    Food and Drug Adminstration. E8 General Considerations for Clinical Trials. 1997. Available at: (accessed 10 September 2007).
  • 39
    Altman D. Practical Statistics for Medical Research. London: Chapman and Hall, 1991: 456.
  • 40
    Greenhalgh T. How to read a paper. Statistics for the non-statistician. I: Different types of data need different statistical tests. BMJ 1997; 315: 3646.
  • 41
    Food and Drug Administration. Patient Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2006. Available at: (accessed 24 July 2007).
  • 42
    European Medicines Agency. Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products. 2005. Available at: (accessed 10 December 2007).
  • 43
    McColl E, Junghard O, Wiklund I, Revicki DA. Assessing symptoms in gastroesophageal reflux disease: How well do clinicians’ assessments agree with those of their patients? Am J Gastroenterol 2005; 100: 118.
    Direct Link:
  • 44
    McColl E. Best practice in symptom assessment: a review. Gut 2004; 53(Suppl. 4): iv4954.
  • 45
    Fallone CA, Guyatt GH, Armstrong D, et al. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2004; 20: 11619.
  • 46
    Veldhuyzen van Zanten S, Talley N, Bytzer P, Klein K, Whorwell P, Zinsmeister A. Rome II: the Functional Gastrointestinal Disorders 1999. In: Drossman, Carazziari, Talley, Thompson, Whitehead, and the Rome II International Working Teams, ed. Design of Treatment Trials for the Functional Gastrointestinal Disorders. MacLean, VA, USA: Degnon Associates, 2000: 577622.
  • 47
    Lauritsen K, Degl’ Innocenti A, Hendel L, et al. Symptom recording in a randomised clinical trial: paper diaries vs. electronic or telephone data capture. Control Clin Trials 2004; 25: 58597.
  • 48
    Hyland ME, Kenyon CA, Allen R, Howarth P. Diary keeping in asthma: comparison of written and electronic methods. BMJ 1993; 306: 4879.
  • 49
    Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Control Clin Trials 2003; 24: 18299.
  • 50
    Stanghellini V, Armstrong D, Monnikes H, Bardhan KD. Systematic review: Do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther 2004; 19: 46379.
  • 51
    Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7: 7583.
  • 52
    Allen CJ, Parameswaran K, Belda J, Anvari M. Reproducibility, validity, and responsiveness of a disease-specific symptom questionnaire for gastroesophageal reflux disease. Dis Esophagus 2000; 13: 26570.
  • 53
    Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28: 6817.
  • 54
    Rothman M, Farup C, Stewart W, Helbers L, Zeldis J. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci 2001; 46: 15409.
  • 55
    Williford WO, Krol WF, Spechler SJ. Development for and results of the use of a gastroesophageal reflux disease activity index as an outcome variable in a clinical trial. VA Cooperative Study Group on Gastroesophageal Reflux Disease (GERD). Control Clin Trials 1994; 15: 33548.
  • 56
    Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 527.
    Direct Link:
  • 57
    Ducrotte P, Zerbib F. ReQuest: a new questionnaire for the simultaneous evaluation of symptoms and well-being in patients with gastro-oesophageal reflux. Digestion 2007; 75(Suppl. 1): 7986.
  • 58
    Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
  • 59
    Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005; 8(Suppl. 1): S924.
  • 60
    Wyrwich KW, Tardino VM. A blueprint for symptom scales and responses: measurement and reporting. Gut 2004; 53(Suppl. 4): iv458.
  • 61
    Bytzer P. Information bias in endoscopic assessment. Am J Gastroenterol 2007; 102: 15857.
    Direct Link:
  • 62
    Junghard O, Carlsson R, Lind T. Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials. Scand J Gastroenterol 2003; 38: 11979.
  • 63
    Fraser A, Delaney B, Moayyedi P. Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol 2005; 100: 44252.
    Direct Link:
  • 64
    Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al. Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Aliment Pharmacol Ther 2006; 23: 5219.
  • 65
    Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001; 96: 19982004.
    Direct Link:
  • 66
    Sharma N, Donnellan C, Preston C, Delaney B, Duckett G, Moayyedi P. A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials. Gut 2004; 53(Suppl. 4): iv5865.
  • 67
    Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130: 153851.
  • 68
    Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. 2): II6977.
  • 69
    Mangel AW, Hahn BA, Heath AT, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998; 26: 7681.
  • 70
    Muller-Lissner S, Koch G, Talley NJ, et al. Subject’s Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 2003; 56: 3106.
  • 71
    Whitehead WE, Palsson OS, Levy RL, Feld AD, VonKorff M, Turner M. Reports of “satisfactory relief” by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006; 101: 105765.
    Direct Link:
  • 72
    Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 85763.
  • 73
    Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 90714.
  • 74
    Zacny J, Zamakhshary M, Sketris I, Van Zanten SV. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 2005; 21: 1299312.
  • 75
    Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut 2004; 53: iv124.
  • 76
    Coyne KS, Wiklund I, Schmier J, Halling K, Degl’ Innocenti A, Revicki D. Development and validation of a disease-specific treatment satisfaction questionnaire for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 18: 90715.
  • 77
    Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996; 38: 64954.
  • 78
    Wiklund I, Carlsson J, Vakil N. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 2006; 101: 1828.
    Direct Link:
  • 79
    Ronkainen J, Aro P, Storskrubb T, et al. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population – the Kalixanda study. Aliment Pharmacol Ther 2006; 23: 172533.
  • 80
    Van Zanten SV, Armstrong D, Barkun A, Junghard O, White RJ, Wiklund IK. Symptom overlap in patients with upper gastrointestinal complaints in the Canadian confirmatory acid suppression test (CAST) study: further psychometric validation of the reflux disease questionnaire. Aliment Pharmacol Ther 2007; 25: 108797.
  • 81
    Monnikes H, Bardhan KD, Stanghellini V, Berghofer P, Bethke TD, Armstrong D. Evaluation of GERD symptoms during therapy: Part II. Psychometric evaluation and validation of the new questionnaire ReQuestTM in erosive GERD. Digestion 2004; 69: 23844.
  • 82
    Armstrong D, Monnikes H, Bardhan KD, Stanghellini V. The construction of a new evaluative GERD questionnaire – methods and state of the art. Digestion 2004; 70: 718.
  • 83
    Bardhan KD, Stanghellini V, Armstrong D, Berghofer P, Gatz G, Monnikes H. Evaluation of GERD symptoms during therapy: Part I. Development of the new GERD Questionnaire ReQuestTM. Digestion 2004; 69: 22937.
  • 84
    Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 2: CD003245.
  • 85
    Thjodleifsson B, Rindi G, Fiocca R, et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 2003; 17: 34351.
  • 86
    Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 148793.
    Direct Link:
  • 87
    Dubois RW, Aguilar D, Fass R, et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity. Aliment Pharmacol Ther 2007; 25: 487500.
  • 88
    Cremonini F, Wise J, Moayyedi P, Talley NJ. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol 2005; 100: 122632.
    Direct Link:
  • 89
    Achem SR, Kolts BE, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997; 42: 213845.
  • 90
    Bautista J, Fullerton H, Briseno M, Cui H, Fass R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain - A randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2004; 19: 112330.
  • 91
    Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115: 429.
  • 92
    Pandak WM, Arezo S, Everett S, et al. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. J Clin Gastroenterol 2002; 35: 30714.
  • 93
    Xia HH, Lai KC, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther 2003; 17: 36977.
  • 94
    Dickman R, Emmons S, Cui H, et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2005; 22: 54755.
  • 95
    Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; 2: CD003244.
  • 96
    Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 8592.
  • 97
    Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 17280.
  • 98
    Pandolfino JE, Vakil NB, Kahrilas PJ. Comparison of inter- and intraobserver consistency for grading of esophagitis by expert and trainee endoscopists. Gastrointest Endosc 2002; 56: 63943.
  • 99
    Sharma P, Wani S, Bansal A, et al. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology 2007; 133: 45464; quiz 674.
  • 100
    Kiesslich R, Kanzler S, Vieth M, et al. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis 2004; 22: 2217.
  • 101
    Van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006; 3: CD002095.
  • 102
    Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 2528.
  • 103
    Sonnenberg A, El-Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999; 72: 8192.
  • 104
    Furuta GT, Straumann A. Review article: the pathogenesis and management of eosinophilic oesophagitis. Aliment Pharmacol Ther 2006; 24: 17382.
  • 105
    Desai TK, Stecevic V, Chang CH, Goldstein NS, Badizadegan K, Furuta GT. Association of eosinophilic inflammation with esophageal food impaction in adults. Gastrointest Endosc 2005; 61: 795801.
  • 106
    Potter JW, Saeian K, Staff D, et al. Eosinophilic esophagitis in adults: an emerging problem with unique esophageal features. Gastrointest Endosc 2004; 59: 35561.
  • 107
    Gonsalves N, Policarpio-Nicolas M, Zhang Q, Rao MS, Hirano I. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006; 64: 3139.
  • 108
    Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: The AGA Chicago Workshop. Gastroenterology 2004; 127: 31030.
  • 109
    Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol 2002; 97: 188895.
    Direct Link:
  • 110
    Ofman JJ, Shaheen NJ, Desai AA, Moody B, Bozymski EM, Weinstein WM. The quality of care in Barrett’s esophagus: endoscopist and pathologist practices. Am J Gastroenterol 2001; 96: 87681.
    Direct Link:
  • 111
    Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 13929.
  • 112
    Dekel R, Wakelin DE, Wendel C, et al. Progression or regression of Barrett’s esophagus--is it all in the eye of the beholder? Am J Gastroenterol 2003; 98: 26125.
  • 113
    Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000; 95: 166976.
  • 114
    Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett’s high-grade dysplasia. Am J Gastroenterol 2000; 95: 188893.
    Direct Link:
  • 115
    Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg 1999; 230: 4338; discussion 438–40.
  • 116
    Kara MA, Peters FP, Rosmolen WD, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy 2005; 37: 92936.
  • 117
    Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ 2006; 332: 114.
  • 118
    Blondeau K, Dupont LJ, Mertens V, Tack J, Sifrim D. Improved diagnosis of gastro-oesophageal reflux in patients with unexplained chronic cough. Aliment Pharmacol Ther 2007; 25: 72332.
  • 119
    Raj AA, Birring SS. Clinical assessment of chronic cough severity. Pulm Pharmacol Ther 2007; 20: 3347.
  • 120
    Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101: 264654.
    Direct Link:
  • 121
    Gatta L, Vaira D, Sorrenti G, Zucchini S, Sama C, Vakil N. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007; 25: 38592.
  • 122
    Vaezi MF, Lopez R, Hicks DM, Abelson TI, Milstein C. What is the optimal initial therapy duration for patients with suspected GERD-related laryngitis? Gastroenterology 2006; 130: A140.
  • 123
    Food and Drug Administration. Patient Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2006. Available at: (accessed 24 June 2007).
  • 124
    Park W, Hicks DM, Khandwala F, et al. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope 2005; 115: 12308.
  • 125
    Hicks DM, Ours TM, Abelson TI, Vaezi MF, Richter JE. The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice 2002; 16: 56479.
  • 126
    Vavricka SR, Storck CA, Wildi SM, et al. Limited diagnostic value of laryngopharyngeal lesions in patients with gastroesophageal reflux during routine upper gastrointestinal endoscopy. Am J Gastroenterol 2007; 102: 71622.
    Direct Link:
  • 127
    Falk GW. Laryngopharyngeal reflux: beauty is in the eye of the beholder. Gastroenterology 2007; 133: 137981.
  • 128
    Larrain A, Carrasco E, Galleguillos F, Sepulveda R, Pope CE, II. Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux. Chest 1991; 99: 13305.
  • 129
    Sontag SJ, O’Connell S, Khandelwal S, et al. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol 2003; 98: 98799.
  • 130
    Field SK, Gelfand GA, McFadden SD. The effects of antireflux surgery on asthmatics with gastroesophageal reflux. Chest 1999; 116: 76674.
  • 131
    Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006; 173: 10917.
  • 132
    Field SK, Sutherland LR. Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux?: a critical review of the literature. Chest 1998; 114: 27583.
  • 133
    Littner MR, Leung FW, Ballard ED II, Huang B, Samra NK. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest 2005; 128: 112835.
  • 134
    Munoz JV, Herreros B, Sanchiz V, et al. Dental and periodontal lesions in patients with gastro-oesophageal reflux disease. Dig Liver Dis 2003; 35: 4617.
  • 135
    Bohmer CJ, Klinkenberg-Knol EC, Niezen-de Boer MC, Meuwissen PR, Meuwissen SG. Dental erosions and gastro-oesophageal reflux disease in institutionalized intellectually disabled individuals. Oral Dis 1997; 3: 2725.
  • 136
    Schroeder PL, Filler SJ, Ramirez B, Lazarchik DA, Vaezi MF, Richter JE. Dental erosion and acid reflux disease. Ann Intern Med 1995; 122: 80915.
  • 137
    Weaver EM. Association between gastroesophageal reflux and sinusitis, otitis media, and laryngeal malignancy: a systematic review of the evidence. Am J Med 2003; 115(Suppl. 3A): 81S9S.
  • 138
    Groen JN, Smout AJ. Supra-oesophageal manifestations of gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003; 15: 133950.
  • 139
    El-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology 1997; 113: 75560.